Costa YC, Mauro V, Fairman E, Charask A, Olguín L, Cáceres L, Barrero C. Prognostic Value of Insulin Resistance Assessed by HOMA-IR in Non-Diabetic Patients with Decompensated Heart Failure.
Curr Probl Cardiol 2022;
48:101112. [PMID:
35007641 DOI:
10.1016/j.cpcardiol.2022.101112]
[Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2022] [Accepted: 01/03/2022] [Indexed: 12/30/2022]
Abstract
The predictive value of insulin resistance in patients hospitalized with heart failure is unknown.
OBJECTIVE
To evaluate prognostic value of insulin resistance (defined by a HOMA IR ≥ 2.5) for the combined event of death and readmission at 90 and 365 days post discharge and to determine if there are differences according to ejection fraction.
METHODS
prospective study of 156 p hospitalized for acute heart failure without diabetes.
RESULTS
83 years, 48% female, EF≤45% 48%. 28% presented HOMA ≥2.5. HOMA IR ≥2.5 was associated with combined event (OR 2.4; 95% CI 1.9-5.1; p 0.02) at 90 days. A multivariate analysis demonstrated its independent predictive value (OR 2.5, 95% CI 1.1-5.8; p: 0.03). At one year follow-up HOMA IR did not predict events. The predictive value of HOMA-IR was not associated with ventricular function.
CONCLUSIONS
HOMA IR index was a predictor of a combined event at 90 days in our population. It is a simple determination that could contribute to identify higher risk patients during this vulnerable post-discharge phase. These data must be validated in larger studies.
Collapse